课题基金 / 基金详情

ApoA1 Determining HDL Subclasses and Atherosclerosis

ApoA1 Determining HDL Subclasses and Atherosclerosis
ApoA1 确定 HDL 亚类和动脉粥样硬化
批准号:
7124318
负责人:
GODFREY Shalom GETZ
金额:
$37.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-01 至 2007-07-31

项目摘要

项目成果

GODFREY Shalom GETZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): HDL, both in humans and animal models, has been shown to be atheroprotective. Human HDL is heterogeneous and consists of two major subclasses, HDL2 and HDL3. Epidemiological studies suggest that HDL2 is more atheroprotective than HDL3. Mice and pigs have a monophasic HDL profile. In mice the HDL is close in size and density to human HDL2, and in pigs it is similar to HDL3. The primary goals of this proposal are to generate a mouse model in which HDL2 or HDL3 are the predominant HDL subclass and to test the atheroprotective effects of HDL2 and HDL3 in a well characterized murine atherosclerotic model. In the first specific aim we will use site-directed mutagenesis to make human apoA-I mutants or human/mouse and human/pig chimeric apoA-I and determine if they demonstrate a preferential association in vitro with mature human HDL2 or HDL3, respectively. Our goal is to generate a protein with minimum sequence differences from human apoA-I. Based on our preliminary data we will initially focus on the interhelical turn between helices 7/8. This turn region will be substituted with human interhelical turns containing proline residues or with interhelical turns from mouse or pig. Our second aim will be to demonstrate that selected apoAI mutants characterized in specific aim 1 can generate HDL2 and HDL3 in vivo in apoA-I deficient mice by adenoviral mediated gene transfer. The, third specific aim will test the efficacy of the engineered HDL2 and HDL3 in protecting against the development of atherosclerosis in human apoB transgenic mice expressing, as knockin genes, the apoA-I proteins that best form HDL2 and HIDL3. The final specific aim will examine how the mutants or the engineered HDLs generated in vivo interact with enzymes and receptors that are involved in HDL remodeling and cholesterol efflux.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.
含有脯氨酸残基的apoA-I模拟肽比4F肽具有更强的体内HDL结合和抗炎能力。
DOI: 10.1194/jlr.m900151-jlr200
发表时间: 2009
期刊: Journal of lipid research
影响因子: 6.5
作者: [Wool,GeoffreyD, Vaisar,Tomas, Reardon,CatherineA, Getz,GodfreyS]
通讯作者: Getz,GodfreyS
Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.
脱辅基蛋白 A-I 的遗传控制和动脉粥样硬化保护:来自近交系小鼠的一些见解。
DOI: 10.1097/mol.0000000000000442
发表时间: 2017
期刊: Current opinion in lipidology
影响因子: 4.4
作者: [Getz,GodfreyS, Reardon,CatherineA]
通讯作者: Reardon,CatherineA
DOI: 10.2174/138161210793292492
发表时间: 2010
期刊: Current pharmaceutical design
影响因子: 3.1
作者: [Getz GS, Wool GD, Reardon CA]
通讯作者: Reardon CA
Biological properties of apolipoprotein a-I mimetic peptides.
载脂蛋白 a-I 模拟肽的生物学特性。
DOI: 10.1007/s11883-010-0097-4
发表时间: 2010
期刊: Current atherosclerosis reports
影响因子: 5.8
作者: [Getz,GodfreyS, Wool,GeoffreyD, Reardon,CatherineA]
通讯作者: Reardon,CatherineA
NKT cells in lipoprotein Metabolism and atherosclerosis
  • 批准号:
    7769517
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2008
  • 负责人:
    GODFREY Shalom GETZ
  • 依托单位:
NKT cells in lipoprotein Metabolism and atherosclerosis
  • 批准号:
    7464157
  • 项目类别:
  • 资助金额:
    $37.2万
  • 财政年份:
    2008
  • 负责人:
    GODFREY Shalom GETZ
  • 依托单位:
Receptors Mediating Lymphotoxin Effects on Athersclerosis
  • 批准号:
    7774401
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2008
  • 负责人:
    GODFREY Shalom GETZ
  • 依托单位:
NKT cells in lipoprotein Metabolism and atherosclerosis
  • 批准号:
    7622124
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2008
  • 负责人:
    GODFREY Shalom GETZ
  • 依托单位:
海外基金